Preventing relapse after a half-matched transplant with modified donor cells
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a half-matched stem cell transplant (haploidentical donor) after a reduced-intensity regimen (RIC) for a blood cancer.
- You and your donor gave written consent to join the study.
- You are not currently taking prednisone (or a similar steroid).
- You are not taking mycophenolate mofetil, and you’re not on cyclosporine or tacrolimus at therapeutic blood levels.
- You do not have significant “graft-versus-host disease” (GvHD): no acute GvHD grade 2 or higher, and no chronic moderate-to-severe GvHD.
- Your disease is not progressing, and you have not already had a second transplant.
- You are not pregnant or nursing, and you can use effective birth control during the study.
- You can follow the study plan and understand instructions (language/mental health/dementia can affect this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests giving special immune cells to patients who had a stem cell transplant and are at high risk for viral infections. The cells may help prevent or fight infections like CMV and EBV after transplant.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial is testing a new way to treat blood cancers that have come back after a stem cell transplant and haven't responded to standard donor cell therapy. The treatment uses special immune cells that are modified to avoid attacking the body, which may help fight the cancer without causing graft-versus-host disease.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.